Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab), Panzem NCD, Panzem® NCD
Panzem NCD, Avastin · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Panzem NCD | DRUG | 2000 mg q8h, continuous dosing in 28 day cycles |
| Temozolomide | DRUG | Fixed dose |
| Panzem® NCD | DRUG | NCD suspension, 1500 mg TID daily for 6 week cycles |
| Sunitinib Malate | DRUG | Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle |
| Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15 |
Inclusion Criteria: 1. A histologically confirmed diagnosis of a recurrent/progressive primary WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma). Patients with recurrent disease whose diagnostic pathology confirmed WHO grade IV malignant glioma (glioblastoma multiforme or glios...
Panzem NCD is an investigational small molecule cancer therapy developed by CASI Pharmaceuticals, Inc. (ticker CASI). It has been studied in Phase 2 clinical trials for carcinoid tumor, metastatic renal cell carcinoma, prostate cancer, and recurrent glioblastoma multiforme. It is also known as 2-methoxyestradiol nanocrystal colloidal dispersion.
Panzem NCD has been studied in Phase 2 trials for several cancers: carcinoid tumor, metastatic renal cell carcinoma, hormone-refractory prostate cancer, and recurrent glioblastoma multiforme. It has been tested both as a single agent and in combination with other therapies such as temozolomide, sunitinib malate, and Avastin (bevacizumab).
Panzem NCD is developed by CASI Pharmaceuticals, Inc., which trades under the ticker CASI. The company has sponsored Phase 2 clinical studies of the drug across multiple oncology indications, including carcinoid tumor, metastatic renal cell carcinoma, prostate cancer, and recurrent glioblastoma multiforme.
Panzem NCD is in Phase 2 clinical development. All four of its registered trials were Phase 2 studies, and all have been completed. The drug is investigational and has not been approved by the FDA for any indication.
Panzem NCD has been evaluated in four completed Phase 2 trials: NCT00481455 in recurrent glioblastoma multiforme with temozolomide, NCT00444314 in metastatic renal cell carcinoma alone and with sunitinib malate, NCT00394810 in hormone-refractory prostate cancer, and NCT00328497 in metastatic carcinoid tumors with Avastin.
No. Panzem NCD and Avastin are different drugs. Panzem NCD, also called 2-methoxyestradiol NCD, is a small molecule developed by CASI Pharmaceuticals. Avastin, also known as bevacizumab, was studied in combination with Panzem NCD in a Phase 2 trial in metastatic carcinoid tumors (NCT00328497).